Please wait…

Login required

Username or email:

To use this function please log-in
If you haven't got an account on, you have the opportunity to register regist here for free.

add instrument

UBS (Lux) Equity Fund - Biotech (USD) P-acc

UBS (Lux) Equity Fund - Biotech (USD) P-acc

ISIN LU0069152568 | WKN 986327 | Mnemonic UBFC | Type fund
23/04/2018 08:24
Bid Ask
This product is subject to quotation restrictions.
Change from Prev. Day -2.36 EUR / -0.52%
Spread absolute / relative 6,76 / 1,49%

Net Asset Value

Previous Day 575.40 USD Date 19/04/2018

Price Information

Last Price 453.6600
Date / Time 23.04.2018 / 08:24:03
Price -
Volume in euro -
Volume Size -
High 453.660
Low 453.660
52 week High 543.800
52 week Low 439.610
Trading Hours 09:00 - 18:00

Price History

Date Opening Price Closing Price Daily High Daily Low Volume (pcs.)
20/04/2018 455.4700 456.0200 456.0200 455.4700
19/04/2018 459.9000 459.9000 459.9000 459.9000
18/04/2018 461.9100 461.9100 461.9100 461.9100
17/04/2018 451.8700 451.8700 451.8700 451.8700
16/04/2018 458.3200


Management Fee 1.63 %
Custodian Fee -
Capital forming savings possible? no
Savings Plan yes
Distribution Non Distributing

Frankfurt Trading Parameters

Continous Quotation no
Minimum tradeable Unit 1

Rating for UBS (Lux) Equity Fund - Biotech (USD) P-acc

€uro FondsNote 3
Lipper Leaders, 3 years
Lipper Leaders, 5 years
Lipper Leaders, 10 years
Lipper Leaders, overall


Fundamental Data

WKN 986327
ISIN LU0069152568
Name UBS (Lux) Equity Fund - Biotech (USD) P-acc
Investment Company UBS (L) Fund Management
Issued in Luxemburg
Issue Date 15/10/1996
Category Aktienfonds Biotechnologie
currency USD
Volume 1,034,853,992.89
Depositary Bank UBS Europe SE, Luxembourg Branch
Paying Agent UBS Europe SE, Niederlassung Deutschland
Fund Management UBS Global Asset Mgt.
Fiscal Year-End 30.11.
Last Update 15/03/2018

Investment policy

invest like UBS (Lux) Equity Fund - Biotech (USD) P-acc: Der Fonds investiert weltweit in Aktien von Unternehmen, die in der Forschung, Produktentwicklung, Herstellung und/oder im Vertrieb im Bereich Biotechnologie tätig sind. Die Auswahl der Unternehmen erfolgt hauptsächlich auf der Basis der folgenden Kriterien: strategische Ausrichtung, starke Marktposition, erstklassiges Management, solide wissenschaftliche Grundlage, Wachstumspotenzial und Verbesserung des Shareholder-Value. Der Fonds ist nach Anwendungsbereich, Marktkapitalisierung, Entwicklungsstadium und Herkunftsland diversifiziert und weist daher ein optimiertes Risiko/Ertrags-Profil auf.

The following Disclaimer and Information has been prepared by Voltabox AG (the “Issuer”) for the purpose of publishing THE securities prospectus by the issuer. Deutsche Boerse AG does not assume any responsibility for the content of the issuer`s Disclaimer and information.


Important Information


The information contained on the following web pages is directed only at persons who are resident of or domiciled in the Federal Republic of Germany (“Germany”) or the Grand Duchy of Luxembourg (“Luxembourg”). The following information does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities. No offer of securities of the Issuer is being, or will be, made to the public outside Germany and Luxembourg. The offer in Germany and Luxembourg is being made solely on the basis of the securities prospectus (including any amendments thereto) which has been approved by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and which has been published on the Issuer’s website. Any investment decision regarding the publicly offered securities of the Issuer should only be made on the basis of the securities prospectus. The securities prospectus is available free of charge from the Issuer (Artegastraße 1, 33129 Delbrück, Germany; Tel.: +49 (0)5250 9930-900; Fax: +49 (0)5250 9762-102) and on the Issuer’s website (

The information contained on the following web pages is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States of America (“United States”), Canada, Australia or Japan. The Issuer’s shares, and the securities offered in the course of the offer, have not been and will not be registered under the US Securities Act of 1933, as amended (“Securities Act”), or with any other securities regulatory authority of any state or other jurisdiction of the United States and may not be offered, sold or delivered within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The Issuer does not intend to register the offer or parts thereof in the United States or make an offer to the public in the United States, Canada, Australia or Japan.

The information contained on the following web pages is not for distribution to persons who are located in the United States, Canada, Australia or Japan or any other jurisdiction where the offer of the securities to the public is not taking place. Any violation of these restrictions may constitute a breach of the securities laws of these countries. The copying, forwarding or other transmission of the content of the following web pages is prohibited.

By clicking the "I AGREE" button below, you warrant that (i) you have read and accepted the foregoing information and restrictions in full and (ii) you are a resident of or domiciled in Germany or Luxembourg, and (iii) you agree not to distribute or forward the information contained on the following web pages to any person who is not a resident of or domiciled in Germany or Luxembourg.


We regret that, due to regulatory restrictions, we are unable to provide you with access to the following web pages.